CARLSMED Stock Price, News & Analysis

Carlsmed, Inc. (Nasdaq: CARL) is a medical technology company that focuses on AI-enabled personalized spine surgery solutions. Across its disclosures and press releases, Carlsmed consistently describes its mission as improving outcomes and decreasing the cost of healthcare for spine surgery and beyond. The company operates in the healthcare sector and is associated with health information and surgical technology services through its use of artificial intelligence and data-driven planning in spine fusion procedures.

Carlsmed designs, manufactures, and markets aprevo, a technology platform for spine fusion surgery procedures. According to the company’s description, the aprevo Technology Platform consists of AI-enabled software solutions, interbody implants that are custom designed for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments. Company materials explain that this platform combines AI-enabled preoperative planning with patient-specific interbody implants to enable predictable alignment tailored to individual patient anatomy and pathology. Carlsmed states that it is focused on becoming the standard of care for spine fusion surgery.

Personalized spine surgery and the aprevo platform

Carlsmed’s public communications describe aprevo as a personalized spine platform that uses 3D preoperative planning and patient-specific, anatomically designed interbody implants. In clinical data cited by the company, 3D planning combined with these personalized implants has been associated with lower mechanical complication–related reoperations in complex adult spinal deformity surgery compared with conventional stock implants. The company highlights that aprevo is intended to address alignment challenges and limitations associated with traditional, off-the-shelf devices.

The aprevo platform has been developed for lumbar fusion surgery and expanded into cervical applications. Carlsmed has announced a U.S. commercial launch of its aprevo Technology Platform for cervical fusion surgeries and has reported early clinical use in cervical cases. In addition, the company has reported that aprevo cervical procedures received New Technology Add-On Payment (NTAP) reimbursement from the U.S. Centers for Medicare & Medicaid Services (CMS), which it identifies as relevant to its cervical platform.

AI-enabled planning and patient-specific implants

In its press releases, Carlsmed describes its technology as combining AI-enabled preoperative planning with 3D-printed, patient-specific implants. The company states that this approach is designed to tailor spinal alignment and implant geometry to each patient’s anatomy and pathology. By doing so, Carlsmed aims to support more precise restoration of spinal alignment and improved endplate fit, which it associates with potential reductions in revision surgeries and mechanical complications in adult spinal deformity procedures.

Carlsmed’s communications emphasize that aprevo is intended to provide surgeons with greater procedural predictability and to improve clinical outcomes in spine fusion while lowering the total cost of care for the healthcare system. The company links its AI-enabled planning and personalized implants to workflow integration in the operating room and to alignment goals defined during preoperative planning.

Commercial stage and stock market presence

Carlsmed describes itself as a commercial-stage medical technology company. It reports revenue from sales of its aprevo technology platform and associated implants and instruments. The company is listed on Nasdaq under the ticker symbol CARL and has disclosed that it completed an initial public offering and was subsequently added to the Russell 2000 Index as part of a group of companies that had IPOs in the third quarter of 2025. These disclosures indicate that Carlsmed is a small-cap public company within the broader U.S. equity market.

The company has reported rapid year-over-year revenue growth in its quarterly and preliminary annual results, attributing this growth to increased adoption of the aprevo platform and an expanding base of surgeon users. Carlsmed also reports on its gross margins, operating expenses, and non-GAAP measures such as Adjusted EBITDA in its earnings press releases and related SEC filings.

Financial reporting and capital structure

Through its financial press releases and Form 8-K filings, Carlsmed provides information on its revenue, gross profit, operating expenses, net loss, cash and cash equivalents, and debt arrangements. The company has discussed term loans and a revolving line of credit under a loan and security agreement with Customers Bank, including amendments that affect the size of the credit facility, interest terms, and warrant arrangements. These disclosures show that Carlsmed uses a combination of equity capital from its IPO and debt financing to support its operations and growth.

Carlsmed’s filings describe the use of non-GAAP financial measures, including Adjusted EBITDA, and explain the items excluded from these measures, such as interest, taxes, depreciation, amortization, stock-based compensation, and changes in the fair value of warrant liabilities. The company presents reconciliations between GAAP net loss and Adjusted EBITDA in its earnings materials.

Clinical and research context

Carlsmed highlights clinical data related to its aprevo lumbar implants and personalized planning in adult spinal deformity surgery. In a retrospective cohort study published in Global Spine Journal, cited by the company, patients treated with aprevo personalized interbody implants and 3D preoperative planning experienced lower revision rates due to mechanical complications compared with a matched cohort treated with stock implants. The company also references data presented at professional meetings, such as the Scoliosis Research Society Annual Meeting and the Cervical Spine Research Society Annual Meeting, to support the clinical performance of its platform.

These publications and presentations are used by Carlsmed to illustrate the potential clinical value of personalization in spine surgery, including reductions in revision surgeries and mechanical complications and possible improvements in quality of life and economic burden associated with revision procedures.

Market recognition and conferences

Carlsmed participates in healthcare and investor conferences, including the J.P. Morgan Healthcare Conference and the Piper Sandler Healthcare Conference, where its management presents to investors and hosts individual meetings. The company has also announced its inclusion in the Russell 2000 Index, which it characterizes as further recognition of its business and growth following its IPO.

Through these activities and its regular earnings communications, Carlsmed provides investors and other stakeholders with updates on its commercial performance, adoption of the aprevo platform, reimbursement developments, and financing arrangements.

FAQs about Carlsmed, Inc. (CARL)